Rani Therapeutics Holdings, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The filing was signed March 30, 2022. Although the request references 2021 Q4, this is an annual report and the figures below are for the full fiscal year unless stated otherwise.
Business context
Rani is a clinical-stage biotherapeutics company developing the RaniPill oral-delivery platform, intended to deliver biologics into the small-intestinal wall as an alternative to injections. The current device is designed for payloads up to 3 mg; the preclinical RaniPill HC is intended to deliver up to 20 mg. The company has no approved products and no commercial product revenue.
RT-101 (octreotide) completed a Phase 1 trial in Australia; RT-102 (PTH) entered Phase 1 in Australia in March 2022. Other programs were preclinical or in formulation development. The company completed its IPO in August 2021.
Key financial results
| Metric | FY2021 | FY2020 |
|---|---|---|
| Contract revenue | $2.7 million | $0.5 million |
| Research and development expense | $26.5 million | $12.0 million |
| General and administrative expense | $27.8 million | $5.0 million |
| Total operating expenses | $54.3 million | $17.0 million |
| Loss from operations | $51.6 million | $16.5 million |
| Consolidated net loss | $53.1 million | $16.7 million |
| Net loss attributable to Rani Holdings | $8.3 million | Not applicable; no parent-company economic interest before IPO |
| Net cash used in operating activities | $32.2 million | $15.0 million |
| Cash and cash equivalents at year-end | $117.5 million | $73.1 million |
| Total debt at year-end | None | $3.8 million |
FY2021 contract revenue came from the Takeda evaluation agreement, which Takeda elected to terminate; $2.0 million of deferred revenue was recognized upon termination. Revenue is not an indicator of product sales. R&D and G&A rose substantially, including due to higher staffing, public-company costs, and $22.6 million of equity-based compensation associated largely with the IPO and organizational transactions. No meaningful product margin was reported.
Cash flow from investing activities was a $0.5 million use; financing activities provided $77.1 million, including $73.6 million of IPO net proceeds. The Avenue convertible loan and PPP loan were repaid during 2021. Management estimated year-end cash would fund operating and capital requirements for at least 12 months from issuance of the statements, while noting spending could shorten that period.
Material changes, outlook, and risks
- Consolidated net loss increased to $53.1 million from $16.7 million, while operating cash use increased to $32.2 million from $15.0 million.
- Management expects significant ongoing losses and rising R&D and public-company expenses; it does not expect commercial product revenue for several years, if ever. No specific revenue or earnings guidance was provided.
- The company expects to need substantial additional capital to advance clinical programs, manufacturing automation, RaniPill HC, and potential commercialization. Existing resources were not expected to fund pivotal trials. Future financing may dilute shareholders or require unfavorable partnerships or licensing.
- Key execution risks include early-stage clinical evidence, uncertain regulatory pathways for novel biologic-device combination products, manufacturing scale-up, dependence on third-party API and material suppliers without long-term supply agreements, and possible trial delays from COVID-19 or other disruptions.
- Three Rani European patents were challenged by Novo Nordisk at the European Patent Office. One was amended and one revoked in 2021; appeals were pending, and a third opposition remained unresolved. The company said the ultimate loss outcome was not probable or reasonably estimable, but the proceedings could affect European commercialization.
- Rani recorded $3.6 million of 2021 equity-based compensation for awards to employees of ICL and affiliates. ICL is owned by the founder and Executive Chairman’s family and provides facilities and services; net service and rent charges were $1.9 million in 2021. The filing also describes a Tax Receivable Agreement requiring payment to certain continuing owners of 85% of specified realized tax benefits; no liability was recorded at year-end because no triggering exchanges had occurred.
- The dual-class structure concentrates voting power: Class B shares carry 10 votes each, and continuing LLC owners held over 80% of voting power as of March 2022. The company does not expect to pay dividends in the foreseeable future.
Important facts for investors to verify
- Confirm the status and full results of RT-102’s Phase 1 study and the next clinical and regulatory milestones for RT-101 and other programs.
- Track cash, operating cash use, financing needs, and any subsequent equity, debt, or partnership transactions against management’s stated runway.
- Review clinical evidence behind reported device delivery and bioavailability claims, including sample sizes, endpoints, and whether results are independently confirmed.
- Follow the European patent opposition appeals and assess their implications for the company’s intellectual-property position.
- Assess manufacturing automation progress, supplier availability, and the costs and requirements of scaling clinical and commercial production.
- Review future related-party transactions, Tax Receivable Agreement exposure, and the effects of continuing LLC exchanges on ownership and voting control.
Audit and controls: Ernst & Young LLP issued an unqualified opinion on the consolidated financial statements. Management reported disclosure controls were effective at a reasonable-assurance level; the filing did not include management’s internal-control effectiveness assessment or auditor attestation because of the newly public-company transition period.